Abstract
ABSTRACT Background In the CRYSTAL and OPUS studies, adding cetuximab to first-line chemotherapy (CT) improved clinical benefit in patients with KRAS wild-type (wt) metastatic colorectal cancer. In a pooled analysis of these trials, the benefit of treatment according to whether patients had liver-limited disease (LLD) or non-LLD was analyzed. Methods Cox's proportional hazards model for overall survival (OS) and progression-free survival (PFS) or logistic regression model for best overall response and R0 resection were used on individual patient data, stratified by study. Likelihood ratio tests were used to explore interactions. Results Adding cetuximab to CT significantly improved PFS (median 11.9 versus 9.2 months, hazard ratio [HR] 0.53, P = 0.0095) and overall response rate (ORR, 72.0 versus 43.2%, odds ratio 3.51, P Conclusions The OS benefit from adding cetuximab to CT is more pronounced in non-LLD patients, thus strengthening the value of cetuximab in palliative treatment. The LLD status is associated with improved prognosis and may be predictive for response in patients receiving CT + cetuximab, facilitating potentially curative resection. More patients (with R0 resection and longer follow-up) may be needed to confirm an OS benefit from CT + cetuximab in LLD patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
